In 962 adults with type 2 diabetes on metformin, oral orforglipron 3, 12 or 36 mg lowered HbA1c by 1·23–1·56% vs 0·81% with dapagliflozin at 40 weeks (non-inferior; all p<0·0001), but caused more gastrointestinal events (46–54% vs 12%) and discontinuations.
RCTn = 962
Welch et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial